DSE Analyst data: 2026-07-13

ACIFORMULA

ACI Formulations PLC · Pharmaceuticals and Chemicals · Cat A
63/100
Fair
৳153.9

DSE Hexagon

Stands out for constructive price action and a strong earnings record, held back by little dividend.

Value36Financial Health44Dividend20Quality71Momentum72Integrity50

Six lenses, each scored 0–100 from the analysis. Integrity is DSE-specific — it reads how organic the price action is (high = clean, low = concentrated-operator risk). Descriptive only, not a recommendation.

Risks & rewards

Risks (1)

  • ⚠ Thin free float — prone to sharp swings

Rewards (2)

  • ✓ Financial health improving
  • ✓ Earnings trending up

Score breakdown

Price history & performance

52-week high৳159.1
52-week low৳119.2
From 52w high-3.3%
Beta0.82
7D -0.3%
1M +7.2%
3M +11.6%
6M +20.1%
1Y +24.2%
YTD +17.9%

Shareholder returns vs DSEX

ACIFORMULA+2.1%
DSEX+2.4%

ACIFORMULA underperformed the DSEX since Jul 8, 2026 — that's when we started tracking the index, so this window will get longer over time.

Volatility

Annualized volatility30.5%
Daily VaR (95%)-2.75%
Max drawdown (5y)-50.5%
Correlation to market0.59

Typical volatility for a DSE stock. Descriptive only — past volatility is not a forecast.

Technical read

RSI (14)64.8
MACDbullish
Bollingerinside bands (+1.3σ)
Price cycle (Wyckoff)MARKUP
Health trendimproving
Flow pressureaccumulation

Valuation

Fair value141.3 (98.9-183.7)
Upside-8.00%
Dividend yield+1.60%
Fundamental verdictSUSTAINABLE
ConfidenceLOW (re-rate ceiling, not target)

Ownership

Institutional holding24.23%
Foreign holding0.0%
Free float9.75%

Thin free float (9.75%) — a small pool of tradable shares can move sharply on modest volume.

Share structure

Authorized capital৳500mn
Paid-up capital৳472.5mn
Face value৳10
Market lot1
Outstanding shares47,250,000
Last AGM28-12-2025
Fiscal year end30-Jun
Reserve & surplus (ex-OCI)৳3,061.4mn
Other comprehensive income৳33.7mn

Financials

Recent P/E ratio

DateCurrent P/ETrailing P/E
Jul 14, 2026 14.31 21.13
Jul 13, 2026 13.97 20.63
Jul 12, 2026 14.15 20.88
Jul 9, 2026 13.88 20.5
Jul 8, 2026 13.69 20.21
Jul 7, 2026 13.74 20.28

Based on the latest un-audited financial statements. Descriptive only.

Dividend history

202525%
202420%
202325%
202225%
202130%
202020%
201935%
201835%
201735%
201635%

Earnings & NAV

YearEPSNAVDividend
2025 7.85 75.51 25%
2024 6.88 68.94 20%
2023 4.97 64.57 25%
2022 5.14 65.88 25%

Quarterly EPS — FY2026

Q11.85
Q24.64
Half-year6.5
Q31.76
Nine-month8.26

From disclosed annual reports and dividend declarations. Descriptive only, not a forecast.

Levels

Resistance

৳154.1
৳159
৳164
৳169.5

Support

৳152.9
৳147.6
৳142.9
৳137.7

Historical bounce zones

Aug 4, 2024: ৳114.6→৳159.8 +39%
Oct 29, 2024: ৳108→৳131.9 +22%
Jan 19, 2025: ৳113.3→৳139.2 +23%
May 27, 2025: ৳120.1→৳145.2 +21%
Jul 29, 2025: ৳133.2→৳164 +23%
Nov 16, 2025: ৳115→৳140 +22%
Dec 8, 2025: ৳120.3→৳156.8 +30%
Mar 9, 2026: ৳132.2→৳156.3 +18%

Sector peers

Other Pharmaceuticals and Chemicals names, ranked by our analysis score (DSE has no market-cap feed). Descriptive comparison only.

Historical outlook

Based on how similar setups behaved historically — not a prediction of what will happen.

10-day 40% vs 40% market avg Typical move: -6.7% / -1.3% / 6%
30-day 41% vs 42% market avg Typical move: -11.5% / -2.8% / 9.3%

Signals: RSI>70 overbought

Reference levels

Descriptive reference points from the analysis — not instructions to buy or sell.

Entry readdip to 143.9–147.6
Reference stopclose<143.2 (buffer)
Reference targetride/trail; ref 188.3
Timing notebuy dips Jun-Aug; trim Sep-Oct; hold+trail

Elevated (score 140) — acceptable only with real earnings and sponsor backing; artificial-activity lens applies. Phase: ACCUMULATION (11% >200-MA, flow ACC). [fundamentals SUSTAINABLE, payout 32.0%, yield 1.6%]

Market activity

Block activity

Block trade ৳0.7M (1 trade), 0.8× normal public volume, institutional ownership +0.6pp.

My notes

Educational market analysis for the Dhaka Stock Exchange. Descriptive information only — not investment advice, not a buy/sell recommendation, and not from a licensed advisor. Prices and analysis can be delayed or wrong; verify with your broker before acting.